title: Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Ikezoe
authors.forename: Kazuto
authors.initials: K
authors.lastname: Togitani
authors.forename: Taizo
authors.initials: T
authors.lastname: Tasaka
authors.forename: Chie
authors.initials: C
authors.lastname: Nishioka
authors.forename: Akihito
authors.initials: A
authors.lastname: Yokoyama
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000473:pathology; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib